Humaid O Al-Shamsi1,2,3,4, Ibrahim Abu-Gheida2,3,5, Ahmed S Abdulsamad6, Aydah AlAwadhi7, Sadir Alrawi1, Khaled M Musallam3, Banu Arun8, Nuhad K Ibrahim8. 1. Departments of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates. 2. Departments of Radiation Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates. 3. Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates. 4. College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. 5. College of Medicine and Health Sciences, United Arab Emirates University, Abu Dhabi, United Arab Emirates. 6. Department of Oncology, Alzahra Hospital, Dubai, United Arab Emirates. 7. Emirates Oncology Society, Dubai, United Arab Emirates. 8. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
BACKGROUND: The role of somatic mutations in breast cancer prognosis and management continues to be recognized. However, data on the molecular profiles of Arab women are limited. MATERIALS AND METHODS: This was a cross-sectional study based on medical chart review of all Arab women diagnosed with breast cancer at a single institution between 2010 and 2018 who underwent next-generation sequencing with Ampliseq 46-Gene or 50-Gene. RESULTS: A total of 78 Arab women were identified, with a median age at diagnosis of 52.3 years (range: 37-82 years; 38.5% ≤50 years). The majority of patients had stage III or IV disease (74.4%). Next-generation sequencing revealed the following somatic mutation rates: TP53, 23.1%; ATM, 2.6%; IDH1, 2.6%; IDH2, 3.8%; PTEN, 7.7%; PIK3CA, 15.4%; APC, 7.7%; NPM1, 2.5%; MPL, 1.3%; JAK2, 2.5%; KIT, 7.7%; KRAS, 3.8%; and NRAS, 3.8%. CONCLUSION: Our study illustrates frequencies of somatic mutations in Arab women with breast cancer and suggests potential variations from estimates reported in the Western population. These data calls for larger epidemiologic studies considering the evolving role of such mutations in prognostication and personalized management.
BACKGROUND: The role of somatic mutations in breast cancer prognosis and management continues to be recognized. However, data on the molecular profiles of Arab women are limited. MATERIALS AND METHODS: This was a cross-sectional study based on medical chart review of all Arab women diagnosed with breast cancer at a single institution between 2010 and 2018 who underwent next-generation sequencing with Ampliseq 46-Gene or 50-Gene. RESULTS: A total of 78 Arab women were identified, with a median age at diagnosis of 52.3 years (range: 37-82 years; 38.5% ≤50 years). The majority of patients had stage III or IV disease (74.4%). Next-generation sequencing revealed the following somatic mutation rates: TP53, 23.1%; ATM, 2.6%; IDH1, 2.6%; IDH2, 3.8%; PTEN, 7.7%; PIK3CA, 15.4%; APC, 7.7%; NPM1, 2.5%; MPL, 1.3%; JAK2, 2.5%; KIT, 7.7%; KRAS, 3.8%; and NRAS, 3.8%. CONCLUSION: Our study illustrates frequencies of somatic mutations in Arab women with breast cancer and suggests potential variations from estimates reported in the Western population. These data calls for larger epidemiologic studies considering the evolving role of such mutations in prognostication and personalized management.
Authors: Joyce O'Shaughnessy; Angela DeMichele; Cynthia X Ma; Paul Richards; Denise A Yardley; Gail Shaw Wright; Kevin Kalinsky; Ronald Steis; Sami Diab; Gerard Kennealey; Ryan Geschwindt; Wei Jiang; Hope S Rugo Journal: Breast Cancer Res Treat Date: 2018-04-19 Impact factor: 4.872
Authors: Justin Lee; Jennifer Axilbund; W Brian Dalton; Daniel Laheru; Stanley Watkins; David Chu; Karen Cravero; Berry Button; Kelly Kyker-Snowman; Ian Waters; Christopher D Gocke; Josh Lauring; Ben Ho Park Journal: J Natl Compr Canc Netw Date: 2016-12 Impact factor: 11.908
Authors: Reva K Basho; Debora de Melo Gagliato; Naoto T Ueno; Chetna Wathoo; Huiqin Chen; Maryam Shariati; Caimiao Wei; Ricardo H Alvarez; Stacy L Moulder; Aysegul A Sahin; Sinchita Roy-Chowdhuri; Mariana Chavez-MacGregor; Jennifer K Litton; Vincent Valero; Raja Luthra; Jia Zeng; Kenna R Shaw; John Mendelsohn; Gordon B Mills; Debu Tripathy; Funda Meric-Bernstam Journal: Oncotarget Date: 2016-11-22
Authors: Auhood Nassar; Mohamed Abouelhoda; Osman Mansour; Samah A Loutfy; Mohamed M Hafez; M Gomaa; Abeer Bahnassy; Amira Salah El-Din Youssef; Mai M Lotfy; Hoda Ismail; Ola S Ahmed; Amany Abd-Elhameed Abou-Bakr; Abdel-Rahman N Zekri Journal: J Adv Res Date: 2020-04-03 Impact factor: 10.479